Screening Technology Company Nuevolution Raises $13.7M

Jun 19, 2012

|

NEW YORK (GenomeWeb News) – Danish small-molecule lead discovery firm Nuevolution today announced it has raised DKK 80.5 million ($13.7 million).

Proceeds will go toward expansion of Nuevolution's operations directed at identifying small molecule lead compounds against "therapeutically important high value targets," it said. Industrifonden led the financing round. Other participants include Sunstone Capital, SEB Venture Capital, and SEB Utvecklingsstiftelse.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Sharing, But Kinda Sorta

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

This Week in Science

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

Structural Biologist Leads India's CSIR

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

Upward of One Hundred

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Featured White Papers

NGS is Accelerating Therapeutic Antibody Discovery - What Lies Beyond?

iPSC & CRISPR/Cas9 Technologies Enable Precise & Controlled Physiologically Relevant Disease Modeling for Basic & Applied Research

Powerful Bioinformatic Support for Specialized Therapeutic Antibody Discovery

Discovering Neuronal Cell Types

Nov

15

Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Nov

27

Featured Webinar

Defining a Multi-Omics Target Discovery Framework for High-Risk Cancers

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.

Nov

29

Featured Webinar

Glass or Polymer? A Comparison for Use in In Vitro Diagnostic Biochips

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec

06

Featured Webinar

Driving Precision Drug Development - A Novel Approach to Assembling a Comprehensive Disease-Variant Landscape

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.

Main menu